Wall Street analysts expect Iqvia Holdings Inc (NYSE:IQV) to report sales of $2.44 billion for the current quarter, according to Zacks. Six analysts have issued estimates for Iqvia’s earnings, with estimates ranging from $2.43 billion to $2.45 billion. Iqvia posted sales of $1.91 billion during the same quarter last year, which suggests a positive year over year growth rate of 27.7%. The company is expected to announce its next earnings report before the market opens on Wednesday, May 2nd.
On average, analysts expect that Iqvia will report full year sales of $10.13 billion for the current fiscal year, with estimates ranging from $10.11 billion to $10.16 billion. For the next fiscal year, analysts anticipate that the company will post sales of $10.70 billion per share, with estimates ranging from $10.51 billion to $10.82 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that cover Iqvia.
Iqvia (NYSE:IQV) last issued its earnings results on Wednesday, February 14th. The medical research company reported $1.32 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.34 by ($0.02). The firm had revenue of $2.16 billion during the quarter, compared to analyst estimates of $2.14 billion. Iqvia had a net margin of 13.44% and a return on equity of 13.03%. The business’s quarterly revenue was up 10.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.09 earnings per share.
IQV has been the subject of a number of analyst reports. Zacks Investment Research downgraded Iqvia from a “hold” rating to a “sell” rating in a research note on Tuesday, February 20th. Evercore ISI initiated coverage on Iqvia in a research note on Thursday, January 18th. They set an “outperform” rating and a $112.00 price target for the company. Royal Bank of Canada set a $118.00 price target on Iqvia and gave the company a “buy” rating in a research note on Thursday, February 15th. JPMorgan Chase lifted their price target on Iqvia from $115.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Finally, ValuEngine upgraded Iqvia from a “hold” rating to a “buy” rating in a research note on Tuesday, February 20th. Eight analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $110.47.
In other Iqvia news, insider Robert Parks sold 896 shares of Iqvia stock in a transaction that occurred on Thursday, March 15th. The shares were sold at an average price of $105.73, for a total transaction of $94,734.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider James H. Erlinger III sold 10,000 shares of Iqvia stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $100.00, for a total transaction of $1,000,000.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 12,527 shares of company stock worth $1,257,834. Insiders own 6.00% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Winslow Evans & Crocker Inc. bought a new stake in Iqvia during the 4th quarter valued at $123,000. Focused Wealth Management Inc bought a new stake in Iqvia during the 4th quarter valued at $166,000. Valeo Financial Advisors LLC bought a new stake in Iqvia during the 4th quarter valued at $170,000. IFP Advisors Inc bought a new stake in Iqvia during the 4th quarter valued at $200,000. Finally, Livforsakringsbolaget Skandia Omsesidigt bought a new stake in Iqvia during the 4th quarter valued at $209,000. 92.35% of the stock is currently owned by institutional investors.
Shares of IQV traded down $0.80 during trading hours on Monday, hitting $97.27. The stock had a trading volume of 602,628 shares, compared to its average volume of 867,562. The company has a market cap of $20,425.05, a PE ratio of 22.31, a P/E/G ratio of 1.67 and a beta of 0.63. The company has a debt-to-equity ratio of 1.21, a current ratio of 1.19 and a quick ratio of 1.19. Iqvia has a 1-year low of $81.43 and a 1-year high of $110.67.
ILLEGAL ACTIVITY WARNING: This piece was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2018/04/21/2-44-billion-in-sales-expected-for-iqvia-holdings-inc-iqv-this-quarter-2.html.
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.